Abstract #1093
Determination of Tumor Response to Hypoxia-Activated Prodrug TH-302 in Rat Glioma Models
Ashley M Stokes 1 , Charles P Hart 2 , and C. Chad Quarles 1
1
Institute of Imaging Science, Radiology and
Radiological Sciences, Vanderbilt University, Nashville,
TN, United States,
2
Threshold
Pharmaceuticals, California, United States
Tumor hypoxia leads to increased tumor aggressiveness
and chemotherapeutic resistance, which has led to the
development of hypoxia-activated cytotoxic prodrugs,
such as TH-302. As tumor hypoxia is spatially
heterogeneous, and thus response to TH-302 is expected
to vary spatially, there is a need for imaging-based
measures of treatment response. Here, we determined
tumor response to TH-302 in two rat glioma models with
known differences in tumor hypoxia, and functional
diffusion mapping was used to quantify treatment-induced
changes in diffusion characteristics that could be
indicative of response to hypoxia activated drugs such
as TH-302.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
